Evidence map›Paper›PMID 42026095›Full record

ArticleNPJ genomic medicine2026

Immuno-molecular features associated with exceptional recurrence-free survivorship from Ovarian Cancer in the pre-PARP era.

Félix Blanc-Durand, Elisa Yaniz Galende, Gwénaël Ferron, Marie-Christine Kaminsky, Elsa Kalbacher, Sophie Abadie-Lacourtoisie, Florence Joly, Jerome Meunier, Olivier Tredan, Coriolan Lebreton and 17 more

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in NPJ genomic medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03418844 (Living After a Rare Cancer of the Ovary), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03418844 naactive not recruitingnot on this map

Living After a Rare Cancer of the Ovary: Chronic Fatigue, Quality of Life and Late Effects of Chemotherapy

TypeinterventionalSponsorCentre Francois BaclesseRan2018 to 2025Enrolled268ConditionsGerm Cell Tumor, Sex Cord Stromal Tumor, Malignant Non-epithelial Ovarian TumorsArmsSelf-questionnaires of living conditions and quality of life, Cardiac, pulmonary, auditory and biological assessment
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors.

Félix Blanc-DurandMedical Oncology, Gynecology Unit, Gustave Roussy Institute, Villejuif, France.
Elisa Yaniz GalendeINSERM UMR 981, Gustave Roussy Institute, Villejuif, France.
Gwénaël FerronGINECO (Groupe d'Investigateurs Nationaux pour l'Etude des Cancers de l'Ovaire), Paris, France.
Marie-Christine KaminskyICL - Institut de Cancérologie de Lorraine, Vandoeuvre-Les-Nancy, France.
Elsa KalbacherCHU Jean Minjoz, Besançon, France.
Sophie Abadie-LacourtoisieICO - Institut de Cancérologie de l'Ouest, site Paul Papin, Angers, France.
Florence JolyGINECO (Groupe d'Investigateurs Nationaux pour l'Etude des Cancers de l'Ovaire), Paris, France.
Jerome MeunierCentre Hospitalier Régional d'Orléans, Orléans, France.
Olivier TredanGINECO (Groupe d'Investigateurs Nationaux pour l'Etude des Cancers de l'Ovaire), Paris, France.
Coriolan LebretonGINEGEPS (GINEco Group on Early Phase Studies), Paris, France.
Jerome AlexandreGINECO (Groupe d'Investigateurs Nationaux pour l'Etude des Cancers de l'Ovaire), Paris, France.
Alain ZannettiCentre hospitalier de Cholet, Cholet, France.
Christophe LouvetInstitut Mutualiste Montsouris, Paris, France.
Cyriak BlonzGINECO (Groupe d'Investigateurs Nationaux pour l'Etude des Cancers de l'Ovaire), Paris, France.
Nadine DohollouPolyclinique Bordeaux Nord Aquitaine, Bordeaux, France.
Dominique BertonICO Centre René Gauducheau, Saint-Herblain, Paris, France.
Christophe DesauwCentre Hospitalier Régional Universitaire de Lille - Hôpital Huriez, Lille, France.
Elisabeth CarolaGHPSO Site de Sentes, Senlis, France.
Michel FabbroGINECO (Groupe d'Investigateurs Nationaux pour l'Etude des Cancers de l'Ovaire), Paris, France.
Philippe FollanaGINECO (Groupe d'Investigateurs Nationaux pour l'Etude des Cancers de l'Ovaire), Paris, France.
Eric Pujade-LauraineGINECO (Groupe d'Investigateurs Nationaux pour l'Etude des Cancers de l'Ovaire), Paris, France.
Louis MouraniINSERM UMR 981, Gustave Roussy Institute, Villejuif, France.
Audrey Le FormalINSERM UMR 981, Gustave Roussy Institute, Villejuif, France.
Hortense Gaultier De Saint BasileINSERM UMR 981, Gustave Roussy Institute, Villejuif, France.
Catherine GenestieINSERM UMR 981, Gustave Roussy Institute, Villejuif, France.
Etienne RouleauINSERM UMR 981, Gustave Roussy Institute, Villejuif, France.
Alexandra LearyMedical Oncology, Gynecology Unit, Gustave Roussy Institute, Villejuif, France. Alexandra.leary@gustaveroussy.fr.

Funding

ARCAGY-GINECO Translational research Grant 2021
6 · The paper itself

Abstract

High-grade serous ovarian cancer (HGSOC) remains a leading cause of gynecological cancer mortality, with only <15% of patients achieving long-term, relapse-free survival. Using data from the VIVROVAIRE (NCT03418844) and CHIVA (NCT03418844) clinical trials, this study investigated the molecular and immunophenotypic characteristics of long-term recurrence-free survivors (LTS) compared with short-term survivors (STS). Tumor samples from 37 LTS (recurrence-free ≥3 years) and 105 STS were analyzed using next-generation sequencing, BRCA1/RAD51C promoter methylation assays, shallow whole genome and multiplex immunofluorescence. Homologous recombination deficiency (HRD) was defined by BRCA1/2 or RAD51C/D alterations, and genomic instability scores (GIS). Immune profiling included quantification of CD4

Identifiers

PMID42026095
PMCPMC13314978

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.